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Abstract
Purpose of Review Topical therapeutic approaches in local-
ized neuropathic pain (LNP) syndromes are increasingly used
by both specialists and general practitioners, with a potentially
promising effect on pain reduction. In this narrative review,
we describe the available compounds for topical use in LNP
syndromes and address their potential efficacy according to
the literature.
Recent Findings Local anaesthetics (e.g., lidocaine,
bupivacaine and mepivacaine), as well as general anaesthetic
agents (e.g., ketamine), muscle relaxants (e.g., baclofen), cap-
saicin, anti-inflammatory drugs (e.g., diclofenac), salicylates,
antidepressants (e.g., amitriptyline and doxepin), α2 adrener-
gic agents (e.g., clonidine), or even a combination of them
have been tested in various applications for the treatment of
LNP. Few of them have reached a sufficient level of evidence
to support systematic use as treatment options.
Summary Relatively few systemic side effects or drug–drug
interactions and satisfactory efficacy seem to be the benefits of
topical treatments. More well-organized and tailored studies
are necessary for the further conceptualization of topical treat-
ments for LNP.
Keywords Localized neuropathic pain . Topical lidocaine .
Topical ketamine . Topical baclofen . Topical amitriptyline .
Topical clonidine
Introduction
The International Association for the Study of Pain (IASP)
established a clear taxonomy of nociceptive and neuropathic
(NP) pain as two different types of pain in 1994 [1]. The
distinction between them is based on causality. The former
originates from nociceptive receptor activation, while the later
is directly linked to a lesion or disease of either the central or
the peripheral nervous systems [2]. NP features also vary ac-
cording to the location of the lesion within the nervous system,
with the general rule that a more peripheral lesion has more
localized symptoms and signs.
The term localized neuropathic pain (LNP) has been pro-
posed to describe a type of NP that is ‘characterized by con-
sistent and circumscribed area(s) of maximum pain, associat-
ed with negative or positive sensory signs and/or spontaneous
symptoms characteristic of neuropathic pain’ [3], and it is felt
in superficial tissues [4•].
Within the definition of LNP, there is a rationale for use of
topical agents in this type of NP. Indeed, some topical treat-
ments have already been mentioned in several guidelines for
the pharmacological treatment of NP, as well as in clinical
reports, along with more traditional systemic treatments [5••,
6–10] as a stand-alone treatment or as an add-on therapy [11•].
Currently, the treatment of NP can include either systemic or
localized therapies, with localized treatments associated with
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relatively fewer systemic side effects and drug–drug interac-
tions and satisfactory efficacy [12–14].
Localized treatments are based on the pharmacological
characteristics and pharmacodynamic profile of each agent
[15•]. Topical applications are administered through the skin
and produce a clinically useful concentration at only the site of
application without systemic concentrations [9, 14, 16], while
transdermal routes produce their analgesic effect by entering
the systemic circulation and include the same adverse effects
as systemic administration [17]. In this narrative review, we
focus only on topically acting treatments, whereas treatments
that are locally applied but act systemically are not included.
A variety of agents are used in the topical treatments of
LNP, such as anaesthetic agents, muscle relaxants, anti-in-
flammatory, antidepressant drugs or even a combination of
them in various applications, and they offer promising results;
however, few of them have received a sufficient level of sup-
port for systematic use as treatment options [18].
In this report, we describe each topical agent separately and
address the efficacy of their use, according to their individual
action mechanisms, pathology and quality of studies. We de-
fined the papers as having high (grade 1), medium (grades 2
and 3) or low (grades 4 and 5) levels of evidence according to
the ‘Centre for Evidence Based Medicine for Treatment’ clas-
sification [18].
Topical Anaesthetic Agents
In the past, EMLAwas the most used form of topical anaes-
thetic, in which lidocaine 2.5%was associated with prilocaine
2.5% in a eutectic mixture of localized anaesthetics in a cream
vehicle, causing the effects and skin penetration to be variable
[19]. Currently, lidocaine in the form of 5% lidocaine medi-
cated plaster is the most widely studied local anaesthetic agent
for the treatment of LNP [20].
Lidocaine is a sodium channel blocker, and its action is
much less effective in cases of LNP, where Nav 1.7 and 1.8
sodium channels have abnormal and sensitized functions after
a nerve lesion and are thought to be the most important in-
ducers of pain. Nav 1.7 and 1.8 are located on small pain
fibres, and their blockage consequently reduces ectopic dis-
charges, which raises the peripheral ectopic discharge thresh-
old and ameliorates the pain transduction [21]. Comparedwith
EMLA, lidocaine plaster does not affect large myelinated fi-
bres and thus does not cause any paraesthesia and/or numb-
ness [22]. The plaster may have other peripheral actions
through a desensitizing effect of TRPA1 channels, contribut-
ing to ‘non-anaesthetic analgesic’ effects [23]. Therefore, the
reduction in peripheral sensitization could be attributed to
both the blocking of pathological sodium channel expression
and desensitization of TRPA1 channels. Finally, a passive
protective action of the plaster itself has been reported in terms
of reducing mechanical stimuli, which can trigger pain sensa-
tions [24, 25].
The application of 5% lidocaine medicated plaster has
shown important effectiveness for the treatment of post-
herpe t ic neura lg ia (PHN) [26–29] and diabe t ic
polyneuropathy (DPN) [24, 30], which has been supported
by high levels of evidence studies. The use of 5% lidocaine
medicated plaster has shown efficacy, which is not supported
by high level evidence, except for cases of neuropathic
orofacial pain syndrome (NOP) for which only a case report
[31] and a case series [32] are available. Furthermore,
medium-level evidence is available for efficacy in patients
with LNP due to traumatic peripheral nerve injuries [33] and
LNP in the area of cervical radiculopathy [34].
Other anaesthetic agents used for the topical treatment of
LNP include bupivacaine and mepivacaine. In humans,
bupivacaine has been suggested to have a prolonged duration
of action, compared with lidocaine [35]. The use of
mepivacaine, a structural analogue of bupivacaine, showed
laboratory superiority in reducing pressure and heat
hyperalgesia in rats with HIV-related NP, compared to lido-
caine, which affected only heat hyperalgesia in a
concentration-dependent manner [36]. However, its use for
LNP remains on an experimental basis.
General Anaesthetic Agents
Ketamine is a parenteral anaesthetic providing its analgesic
effects in anaesthetic subdoses. The main use of ketamine is
in general anaesthesia, producing analgesia, amnesia, uncon-
sciousness and akinesia in a dose-dependent mode [37]. Its
topical application for LNP relies on a NMDA receptor block-
ade in a non-competitive fashion, and pain modulation occurs
via the blocking of glutamate production. Ionotropic gluta-
mate receptors are expressed on peripheral afferent nerve ter-
minals and the membranes of unmyelinated peripheral axons
in response to local inflammation [38, 39]. Experimental data
in animals suggested that NMDA and non-NMDA glutamate
receptor expression is linked to hyperalgesia and allodynia
[40, 41].
Only a few studies have described the results after the top-
ical application of ketamine alone, as the agent is more com-
monly used in combination with other drugs [42–47]. The
isolated use of 1% ketamine ointment in patients with PHN
showed no significant difference between the active group and
the placebo in a double-blinded RCT crossover study in pa-
tients [48]. Furthermore, according to another RCT, the topical
application of 5% ketamine gel was not proven effective in
cases of DPN [49]. Two more studies with a medium level of
evidence suggested the inefficacy of 0.5 and 1% ketamine
after topical application in patients with PHN, DPN and
post-traumatic NP [50, 51]. On the contrary, good results were
obtained from an open label study of patients with PHN
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treated with a topical application of 0.5% ketamine [52] and in
a case series including patients with complex regional pain
syndrome (CRPS; formerly described as reflex sympathetic
dystrophy (RSD)), lumbar radiculopathy and PHN [53].
Reduced allodynia and hyperalgesia have been reported after
topical ketamine 10% application in patients with CRPS in an
RCT [54] and several case series and case reports using lower
concentrations [55, 56].
Muscle Relaxants
Baclofen is a muscle relaxant traditionally used for the sys-
temic treatment of spasticity. The topical application of baclo-
fen in cases of LNP offers the potential of pain reduction due
to its GABAB receptor agonist features. GABAB receptor
activation entails slow and prolonged inhibitory transmission,
mediated by changes in membrane permeability due to an
intracellular increase in K+ and a decrease in Ca2+ ions [57].
Except for the central nervous system, GABAB receptors are
found in cutaneous layers on C fibres and keratinocytes, and
these receptors thus provide a new target for the topical treat-
ment of LNP [58].
Until now, baclofen is more commonly used in combina-
tion with other topical agents [44, 46, 47, 59, 60].
Effectiveness of single subcutaneous Baclofen 0.01% in re-
ducing thermal hyperalgesia was investigated in mice with
advanced skin cancer and mixed nociceptive and neuropathic
pain [61]. Since then, in only two studies involving humans,
baclofen 5% was used as a single topical agent for the treat-
ment of NP in a case with NP-related to acromegaly as mono-
therapy [62•] and as an add-on therapy in a case with lumbar
hernia-derived NP [63•]. In both studies, topical baclofen ap-
plication was shown to be effective in pain relief. Studies with
a higher level of evidence are not available.
Capsaicin and Analogues
Capsaicin is a natural vanilloid derived from the capsicum
plant. It selectively binds to the transient potential vanilloid
receptor 1 (TRPV1), a well-characterized Ca2+ permeant
polymodal receptor expressed on Aδ and C-nerve fibres and
on the central nervous system. It releases substance P and
causes transient depolarization via sodium and calcium influx.
Chronic exposure to capsaicin overstimulates and desensitizes
its receptors causing defunctionalization [64, 65]. The persis-
tent analgesic effect of topical capsaicin can also be explained
by causing reversible nerve degeneration, including autonom-
ic fibres [66, 67], as well as the depletion of substance P at
nervous afferent endings [64].
Regarding its efficacy, a low concentration capsaicin patch of
0.025 or 0.075% does not seem to be particularly effective in the
treatment of different forms of chronic neuropathic pain based
on a high level of evidence [68]. On the contrary, a subsequent
high level of evidence systematic review of six studies and a
total of 2000 patients reported that the topical use of an 8%
capsaicin patch was more effective than a ‘placebo’ by render-
ing 30–50% significant post-treatment pain relief in patients
with PHN and HIV-distal sensory polyneuropathy (HIV-DSP),
an efficacy that was not achieved with a low-dose capsaicin
patch [69]. A high-dose capsaicin application also proved useful
for cervical and lumbar-related NP in a medium level of evi-
dence study [70]. An open label, multicentre clinical trial,
aiming to compare the efficacy of high-concentration capsaicin
with conservative oral pregabalin therapy in peripheral NP, con-
cluded that the capsaicin 8% patch achieved non-inferior pain
relief compared to an optimized dose of pregabalin with a more
rapid onset of action, fewer systemic adverse responses and
better treatment satisfaction in patients with PHN, post-
traumatic nerve injury and non-diabetic painful peripheral neu-
ropathy [71]. Regarding DPN, a medium level of evidence pro-
spective observational study of 91 cases treated with a single
high-dose capsaicin patch showed a significant reduction in pain
that persisted by week 12 in 34% of the patients [72]. A stronger
level of evidence was suggested several years ago [73]; howev-
er, its broader local application in DPN was not suggested be-
cause the nerve fibre degeneration was caused by capsaicin [67].
Among all topical agents used for the treatment of NP, a
high-dose 8% capsaicin patch was more likely to produce
topical side effects, which included mild to moderate transient
burning in the area of application, pain, erythema, pruritus,
papules, swelling and dryness [74]. Recent data introduced a
new potential superior topical analgesic agent, namely olvanil.
Olvanil is a synthetic non-pungent analogue of capsaicin, and
laboratory data indicated a higher analgesic effect via directly
desensitizing TRPV1 channels, with fewer side effects in top-
ical applications [75].
Non-steroidal Anti-inflammatory Drugs
Peripheral nerve injury induces an inflammatory response
with increased prostaglandin production, which enhances so-
dium currents and calcium influx in peripheral nociceptive
neurons and increases central neurotransmitter release and
the depolarization of second-order nociceptive neurons [76].
The topical application of non-steroidal anti-inflammatory
drugs (NSAIDs) currently plays a crucial role, as they inter-
vene with the inflammatory pathway and interrupt its progres-
sion [77]. When NSAIDs are applied topically, a high concen-
tration is observed in the dermis and muscles (equivalent to
that obtained via the oral route). The minimal systemic ab-
sorption of the active substance should not be totally exclud-
ed, although plasma concentrations were lower than 5% of
those achieved by systemic delivery. Topical application
proved to be completely safe, without topical side effects [78].
Diclofenac has great cyclooxygenase-2 (COX-2) inhibi-
tion, whereas an additional effect on peripheral nociceptors
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has been reported [78] along with the action of TRPV1 and
TRPA1 receptors [79]. Its efficacy has been described exper-
imentally for the treatment of neuropathic orofacial pain, with
good results after 5% topical diclofenac administration [80].
Recently, a medium level of evidence study also introduced
satisfying results in pain relief for patients with PHN and
CRPS after the topical application of 1.5% diclofenac [81].
Ibuprofen and ketoprofen have also been administered topi-
cally in cases of NP syndromes, though always in combina-
tion with other agents [60, 82]. To the best of our knowledge,
no other NSAID drug, except for diclofenac, has been used
topically as a single agent for the treatment of LNP.
Salicylates also interfere with the inflammatory pathway,
presenting strong analgesic features. The topical application
of a mixture of aspirin and diethylether has been tested in
patients with acute herpetic neuralgia and PHN, achieving
excellent results of pain relief, healing acceleration and pre-
vention of the development of PHN after the acute infection
stage. The above findings were confirmed twice, with two
medium level of evidence studies [83•, 84•]. In both studies,
the topical analgesic effect of the mixture of aspirin and
diethylether proved to be superior to the placebo group and
converse to the topical application of diclofenac or indometh-
acin. Furthermore, topical application is linked to better pain
relief results in comparison with the oral route [85, 86].
Antidepressant Agents
Amitriptyline is a tricyclic antidepressant agent, which acts on
many sites, either in the central nervous system by inhibiting
neuronal reuptake of norepinephrine and serotonin or in the
periphery by the blockade of Na+, K+, Ca2+ voltage-gated ion
channels 15–17 and muscarinic, cholinergic, nicotinic, hista-
minergic, α2-adrenergic, adenosine and NMDA receptors
[87–92]. The topical application of amitriptyline in several
concentrations for the treatment of a variety of LNP syn-
dromes has been tested, with ambiguous results, regarding
not only the efficacy but also the site of action. Studies of
single topical applications of 1–5% amitriptyline in various
aetiologies of NP, including PHN, DPN, post-traumatic NP
and painful peripheral neuropathy, did not show statistical
significance in the reduction of pain with a medium level of
evidence [50, 51, 93]. On the contrary, other case reports de-
scribe some efficacy of topical 5–10% amitriptyline applica-
tions in DPN, chronic idiopathic axonal polyneuropathy
(CIAP), CRPS and post-traumatic neuropathic pain with a
low level of evidence [94–96]. Data from these studies indi-
cated that a high concentration of 10% amitriptyline might be
more effective in pain relief; however, it seems to be related to
systemic side effects [95]. Until now, the latest systematic
review did not support the use of topical amitriptyline for
the treatment of LNP, due to a lack of robust evidence [97].
Doxepin is another tricyclic antidepressant agent applied
topically in cases of NP. Its efficacy in pain relief is demon-
strated by medium and low levels of evidence for chronic NP
and CRPS, respectively [98, 99], but no recent studies are
available in the literature.
α2 Adrenergic Agents
Clonidine is an α2-adrenergic receptor agonist that is generally
approved for the treatment of hypertension. Target receptors for
clonidine are the α2 receptors, located centrally in the brain and
spinal cord and peripherally in the dorsal root ganglia, on sen-
sory neurons [100, 101] and on nociceptors [102]. The activa-
tion of these G-protein coupled receptors downregulates adenyl-
ate cyclase and other second messengers related to the initiation
and maintenance of the abnormal excitability of nociceptors
[103]. Clonidine is also an imidazoline-receptor agonist, located
peripherally on peripheral nerve endings. The activation of I2-
imidazoline receptors may be responsible for additional mecha-
nisms of the analgesic activity of topical clonidine applications
[104]. The efficacy of 0.1% topical clonidine application has
been evaluated in cases of DPN, providing a possible contribu-
tion to pain relief with no systemic absorption, with a medium
level of evidence [105–107].
Other Agents
Ambroxol is a well-tolerated agent commonly used for the
treatment of respiratory disorders via its secretolytic,
secretomotor and local anaesthetic effects in cases of
pharyngalgia [108]. Regarding mechanisms of action,
ambroxol is a potent voltage-dependent sodium channel
blocker, blocking these channels approximately 40 times more
strongly than lidocaine [109]. Moreover, it seems to be a pref-
erential blocker of sodium channel subtype Nav 1.8, which is
mostly expressed in nociceptive C-fibre neurons [110–112].
The drug’s efficacy has been tested experimentally in condi-
tions of chronic pain, with good results in pain relief
[113–115]. Recently, a stand-alone case series showed prom-
ising results, with significant effectiveness of topical applica-
tions in seven patients with LNP syndromes [116•]. The au-
thors also stated a potential contribution of the agent in
diminishing allodynia, strongly suggesting further research
for the systematic use of ambroxol in NP treatment [116•].
Features of the abovementioned topical agents used for the
treatment of LNP are summarized in Table 1.
Discussion
Localized neuropathic pain is a recently described form of
peripheral neuropathic pain [3, 4•]. Its description and the
definition of the parameters in which this term can be applied
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gave a stronger rational basis for topical treatments, especially
in the cases of elderly people with low compliance to the oral
consumption of drugs and in patients under polypharmacy.
Topical treatments can be applied as add-on therapy without
overcharging the patient with other orally administered drugs
[11•] and have been associated with relatively fewer systemic
side effects and drug–drug interactions, satisfactory efficacy
and better compliance [12–14].
According to current guidelines for the treatment of periph-
eral NP, only two of the topical agents of this narrative review
are included in the formal treatment of NP, namely, the lido-
caine medicated plaster and the capsaicin patch. Previous rec-
ommendations suggested the use of lidocaine medicated plas-
ter as the first-line treatment for postherpetic neuralgia, espe-
cially in the elderly, and the capsaicin patch as the second- or
third-line treatment for postherpetic neuralgia [8, 9] or the
application of the capsaicin patch as the second-line treatment
for all types of peripheral neuropathic pain except for trigem-
inal neuralgia [7]. However, in a recent update of NeuPSIG
guidelines, lidocaine patches were not recommended as the
first-line treatment because of the weak final quality of evi-
dence. Although, due to an excellent safety profile, high
values and preferences, they were proposed with a weak grade
of recommendation for general use as the second-line of treat-
ment for peripheral NP [5••]. The same update proposed cap-
saicin patches as the second-line of treatment for peripheral
NP because of the high quality of evidence, but modest effect
size, training requirements and potential safety concerns on
sensation with long-term use [5••].
The application of topical agents has shown good results in
LNP; however, the current lack of a high level of evidence in the
related studies prevents a more systematic use. Many of the
studies cited in our review strongly support a better and more
widespread use of various topical compounds. Diversity in study
designs, concentrations and combinations of the substances, pa-
thologies and duration of treatments and follow-up of each study
creates a heterogeneous sample of available information. All
these variables do not show any robust treatment indications,
leading to a lack of guidelines on topical treatments.
The need of tailored protocols in large RCTs with a con-
gruous number of patients, proper randomization, large
follow-up duration and other indicators as the number needed
to treat (NNT), seems to be of high importance for the further
conceptualization of the topical treatment of NP. Current data
suggested that the elderly population and polymedicated pa-
tients with LNP are two population subgroups that could have
the most relevant benefit from the use of topical treatments.
We strongly suggest that the separate evaluation of the
efficacy of each agent should precede the evaluation of com-
binations of agents. Until now, mixtures of topical agents have
been used based either on previous knowledge about the po-
tential efficacy and mechanisms of action or more arbitrarily.
The identification of the effect of each topical compound
separately can avoid several misleading circumstances regard-
ing cost- and time-wasting trials including three to six differ-
ent compounds, with possibly uncertain levels of results.
Conclusion
In conclusion, the field of topical treatments for LNP offers a
challenging area of research, with a possibly high level of po-
tential efficacy. As the current trend indicates ongoing interest
in investigational and experimental agents with plausible pe-
ripheral mechanisms of action, more well-organized and tai-
lored studies are necessary to broaden our treatment options.
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